Canagliflozin Hemihydrate

卡格列净

Report date: 2026/03/20 20:03:07
NMEFirst In Class

Base Information

Drug NameCanagliflozin Hemihydrate
Drug Alias NameCanagliflozina坎格列净Canagliflozinum卡格列净半水Canagliflozine +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitors
TargetsSodium/glucose cotransporter 2
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1 +[13] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2013/03/29
Country/TerritoryCzechiaBelgiumBulgaria +[59] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMitsubishi Tanabe Pharma
China Registration ClassN/A

Develop Information

Active CompaniesMerck & CoJanssen-Cilag International NvJanssen Pharmaceuticals Inc +[16] 
Inactive CompaniesUniversity Of Colorado DenverNational Institute Of Diabetes And Digestive And Kidney DiseasesJohnson & Johnson Pharmaceutical Research & Development LLC
Active IndicationsDiabetes Mellitus, Type 2Diabetes MellitusCoronary Artery Disease +[8] 
Inactive IndicationsObesityDiabetes Mellitus, Type 1Cardiovascular Diseases +[5] 

Other Information

ATC CodeA10BK02
Related LinksWikipediaDrugBankKEGG